Delivery Order HHSN261201500036I-HHSN26100006
Award Date
9/15/17
Potential Completion Date
9/14/19
Potential Value
$636K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35294, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) for the further development of multi-antigen vaccines for the primary and secondary prevention of bladder cancer. The contract has a firm fixed price of $901,729.00 and a period of performance from September 17, 2018 to March 16, 2020, with a final completion date of December 16, 2022. The contract is part of...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB) for the "Evaluation of the Cancer Prevention Efficacy of GLG-302." The $574,237 contract is part of the NCI's Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The contract does not have a set-aside designation. UAB, a public research...
This federal contract was awarded by the National Cancer Institute, part of the Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) to evaluate whether a concurrent retinoid X receptor agonist can enhance the efficacy of the HER2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer. The contract, valued at $930,464.00, is a delivery order under the PREVENT Cancer Program, a preclinical...
This is a Firm Fixed Price delivery order awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Cancer Program (PREVENT) indefinite delivery contract. The contract has a ceiling value of $922,642.00 and no set-aside designation. The contract describes a research and development project in the area of biomedical basic research for the Preclinical Prevention Cancer Program. The work involves conducting preliminary...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to the University of Alabama at Birmingham (UAB). The contract is for the "Evaluation of Agents/Protocols that Inhibit Two Major Pathways Involved in Human Urinary Bladder Cancer (PI3K, EGFR) and Protocols to Reduce Their Toxicity." It is part of the NCI's Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. The contract has a...
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Alabama at Birmingham (UAB) for the evaluation of "clinical-ready" agents (bazedoxifene and lapatinib) in combination for the prevention of estrogen receptor-positive and estrogen receptor-negative mammary cancers. The contract, which is part of the Preclinical Prevent Cancer Program, has a potential value of...
This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer". The potential value of the contract is $492,314.00. The work is being performed under the National Cancer Institute's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" major...
This is a definitive contract awarded by the U.S. government to the University of Alabama at Birmingham (UAB), a non-profit educational institution, on December 15, 2002. The contract has a firm fixed price of $1,497,441.00 and a completion date of June 30, 2007. There is no set-aside designation for this contract. UAB has an extensive track record of delivering biomedical and public health research under federal grant awards from agencies like the National Institutes of Health (NIH), Centers...
The University of Alabama at Birmingham was awarded a $1,044,896 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program master IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for further development of Colovac, a multi-antigen multi-peptide vaccine for colon cancer prevention, in support of the PREVENT Efficacy Pool program. The University of...
The University of Alabama at Birmingham (UAB) was awarded a $42,411,498.54 Definitive Contract by the National Institute of Allergy and Infectious Diseases (NIAID) Division of Extramural Activities (DEA) for biomedical research and services. This is a Cost No Fee contract with an ultimate completion date of December 1, 2013. UAB has a strong track record of securing federal funding for biomedical research, including grants from the National Institutes of Health (NIH). The contract does not...